Breakthroughs in the treatment and prevention of Clostridium difficile infection

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 3, 2016, Pages 150-160

  Kociolek, Larry K ^a   Gerding, Dale N ^b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTOXUMAB; BACTERIAL VACCINE; BEZLOTOXUMAB; CADAZOLID; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE VACCINE; FIDAXOMICIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; RIDINILAZOLE; SUROTOMYCIN; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE INFECTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG FECES LEVEL; DRUG MEGADOSE; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LOW DRUG DOSE; NONHUMAN; NONTOXIGENIC CLOSTRIDIUM DIFFICILE; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SEROCONVERSION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; IMMUNOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84959343182     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.220     Document Type: Review

References (109)

1. Kelly, C. P.,&Lamont, J. T. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359, 1932-1940 (2008
2. Magill, S. S., et al. Multistate point-prevalence survey of health care-Associated infections. N. Engl. J. Med. 370, 1198-1208 (2014
3. Freeman, J., et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23, 529-549 (2010
4. Chitnis, A. S., et al. Epidemiology of community-Associated Clostridium difficile infection, 2009 through 2011. JAMA Intern. Med. 173, 1359-1367 (2013
5. Wendt, J. M., et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 133, 651-658 (2014
6. Le Saux, N., et al. Pediatric Clostridium difficile infection: 6 year active surveillance in a defined patient population. Infect. Control Hosp. Epidemiol. 35, 904-906 (2014
7. Lessa, F. C., et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825-834 (2015
8. U.S. Department of Health and Human Services. Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control and Prevention [online], http://www.cdc.gov/drugresistance/pdf/ar-Threats-2013-508.pdf (2015
9. Dubberke, E. R.,&Olsen, M. A. Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 55, S88-S92 (2012
10. Kelly, C. P.,&Kyne, L. The host immune response to Clostridium difficile. J. Med. Microbiol. 60, 1070-1079 (2011
11. Cohen, S. H., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010
12. Surawicz, C. M., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478-498 (2013
13. Debast, S. B., Bauer, M. P.,&Kuijper, E. J. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. SUPPL 2, 1-26 (2014
14. Committee on Infectious Diseases. Clostridium difficile infection in infants and children. Pediatrics 131, 196-200 (2013
15. Venugopal, A. A.,&Johnson, S. Current state of Clostridium difficile treatment options. Clin. Infect. Dis. 55, S71-S76 (2012
16. Zar, F. A., Bakkanagari, S. R., Moorthi, K. M.,&Davis, M. B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45, 302-307 (2007
17. Johnson, S., et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 59, 345-354 (2014
18. Venugopal, A. A.,&Johnson, S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin. Infect. Dis. 54, 568-574 (2012
19. Shue, Y. K., et al. Safety, tolerance, and pharmacokinetic studies of OPT 80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother. 52, 1391-1395 (2008
20. Credito, K. L.,&Appelbaum, P. C. Activity of OPT 80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48, 4430-4434 (2004
21. Finegold, S. M., et al. In vitro activities of OPT 80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48, 4898-4902 (2004
22. Louie, T. J., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin. Infect. Dis. 55, S132-S142 (2012
23. Louie, T. J., Emery, J., Krulicki, W., Byrne, B.,&Mah, M. OPT 80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53, 261-263 (2009
24. Chang, J. Y., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-Associated diarrhea. J. Infect. Dis. 197, 435-438 (2008
25. Louie, T. J., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431 (2011
26. Cornely, O. A., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12, 281-289 (2012
27. Petrella, L. A., et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin. Infect. Dis. 55, 351-357 (2012
28. Mullane, K. M., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53, 440-447 (2011
29. Bartsch, S. M., Umscheid, C. A., Fishman, N.,&Lee, B. Y. Is fidaxomicin worth the cost? An economic analysis. Clin. Infect. Dis. 57, 555-561 (2013
30. Konijeti, G. G., Sauk, J., Shrime, M. G., Gupta, M.,&Ananthakrishnan, A. N. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin. Infect. Dis. 58, 1507-1514 (2014
31. Nathwani, D., et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J. Antimicrob. Chemother. 69, 2901-2912 (2014
32. Goldstein, E. J., Citron, D. M., Tyrrell, K. L.,&Merriam, C. V. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram negative aerobic and anaerobic intestinal flora isolates. Antimicrob. Agents Chemother. 57, 4872-4876 (2013
33. Vickers, R., et al. A randomised Phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect. Dis. 15, 91 (2015
34. Summit Therapeutics Press Releases. Positive top-line Phase 2 data of ridinilazole in CDI. Summit Therapeutics [online], http://www.summitplc.com/pressreleases/positive-Top-line-phase-2-data-of-ridinilazole-in-cdi/(2015
35. Mascio, C. T., et al. In vitro and in vivo characterization of CB 183, 315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob. Agents Chemother. 56, 5023-5030 (2012
36. Citron, D. M., Tyrrell, K. L., Merriam, C. V.,&Goldstein, E. J. In vitro activities of CB 183, 315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob. Agents Chemother. 56, 1613-1615 (2012
37. Chesnel, L., et al. Treatment of CDAD with oral CB 183 315: time to recurrence, relapse and re infection rates compared with vancomycin. Clin. Microbiol. Infect. 18, 380 (2012
38. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01597505?term=NCT01597505&rank=1 (2015
39. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01598311?term=NCT01598311&rank=1 (2015
40. United States Securities and Exchange Commission. Form 10 Q. United States Securities and Exchange Commission [online], https://www.sec.gov/Archives/edgar/data/310158/000031015815000053/mrk0630201510q.htm (2015
41. Locher, H. H., et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob. Agents Chemother. 58, 892-900 (2014
42. Locher, H. H., et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob. Agents Chemother. 58, 901-908 (2014
43. Louie, T. J., et al. A multicenter, double-blind, randomized, Phase 2 study evaluating the novel antibiotic, cadazolid, in patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 59, 6266-6273 (2015
44. Gerding, D. N., et al. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J. Antimicrob. Chemother. (2015
45. Burnham, C. A.,&Carroll, K. C. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin. Microbiol. Rev. 26, 604-630 (2013
46. Gerding, D. N., et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313, 1719-1727 (2015
47. Villano, S. A., Seiberling, M., Tatarowicz, W., Monnot Chase, E.,&Gerding, D. N. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob. Agents Chemother. 56, 5224-5229 (2012
48. Allen, S. J. The potential of probiotics to prevent Clostridium difficile infection. Infect. Dis. Clin. North Am. 29, 135-144 (2015
49. Evans, C. T.,&Johnson, S. Prevention of Clostridium difficile infection with probiotics. Clin. Infect. Dis. 60, S122-S128 (2015
50. Goldenberg, J. Z., et al. Probiotics for the prevention of Clostridium difficile-Associated diarrhea in adults and children. Cochrane Database Syst. Rev. 5, CD006095 (2013
51. Johnston, B. C., et al. Probiotics for the prevention of Clostridium difficile-Associated diarrhea: a systematic review and meta-Analysis. Ann. Intern. Med. 157, 878-888 (2012
52. Pattani, R., Palda, V. A., Hwang, S. W.,&Shah, P. S. Probiotics for the prevention of antibiotic-Associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta analysis. Open Med. 7, e56-e67 (2013
53. Allen, S. J., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-Associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382, 1249-1257 (2013
54. Aas, J., Gessert, C. E.,&Bakken, J. S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36, 580-585 (2003
55. Tvede, M.,&Rask-Madsen, J. Bacteriotherapy for chronic relapsing clostridium difficile diarrhoea in six patients. Lancet 333, 1156-1160 (1989
56. Drekonja, D., et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review of the evidence. US Department of Veterans Affairs [online], http://www.hsrd.research.va.gov/publications/esp/FecalMicrobiota-REPORT.pdf (2015
57. Drekonja, D., et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann. Intern. Med. 162, 630-638 (2015
58. van Nood, E., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415 (2013
59. Cammarota, G., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy versus vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 41, 835-843 (2015
60. Youngster, I., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin. Infect. Dis. 58, 1515-1522 (2014
61. Hamilton, M. J., Weingarden, A. R., Sadowsky, M. J.,&Khoruts, A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107, 761-767 (2012
62. Lee, C. H., et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315, 142-149 (2016
63. Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A.,&Sadowsky, M. J. High-Throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4, 125-135 (2013
64. Aroniadis, O. C., et al. Long-Term follow up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J. Clin. Gastroenterol. http://dx.doi.org/10.1097/MCG.0000000000000374 (2015
65. Hirsch, B. E., et al. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect. Dis. 15, 191 (2015
66. Youngster, I., et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312, 1772-1778 (2014
67. Borody, T., Fischer, M., Mitchell, S.,&Campbell, J. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev. Gastroenterol. Hepatol. 9, 1379-1391 (2015
68. Pardi, D. S., et al. Ser 109, an oral, microbiome-based therapeutic, is efficacious for the treatment of recurrent C. difficile and eliminates enterobacteriacea and vancomycin-resistant enterococci colonizing the gut. [abstract B-1875a], Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Sept 5-9, 2014 (2014
69. Lawley, T. D., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8, e1002995 (2012
70. Buffie, C. G., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205-208 (2015
71. Bakken, J. S., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 9, 1044-1049 (2011
72. Schwartz, M., Gluck, M.,&Koon, S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am. J. Gastroenterol. 108, 1367 (2013
73. Quera, R., Espinoza, R., Estay, C.,&Rivera, D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J. Crohns Colitis 8, 252-253 (2014
74. Kelly, C. R., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am. J. Gastroenterol. 109, 1065-1071 (2014
75. Baxter, M., Ahmad, T., Colville, A.,&Sheridan, R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin. Infect. Dis. 61, 136-137 (2015
76. De Leon, L. M., Watson, J. B.,&Kelly, C. R. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 11, 1036-1038 (2013
77. Alang, N.,&Kelly, C. R. Weight gain after fecal microbiota transplantation. Open Forum Infect. Dis. 2, ofv004 (2015
78. Shim, J. K., Johnson, S., Samore, M. H., Bliss, D. Z.,&Gerding, D. N. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351, 633-636 (1998
79. Merrigan, M. M., Sambol, S. P., Johnson, S.,&Gerding, D. N. Prevention of fatal Clostridium difficile-Associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188, 1922-1927 (2003
80. Sambol, S. P., Merrigan, M. M., Tang, J. K., Johnson, S.,&Gerding, D. N. Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 186, 1781-1789 (2002
81. Kyne, L., Warny, M., Qamar, A.,&Kelly, C. P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189-193 (2001
82. Lyras, D., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176-1179 (2009
83. Humphreys, D. P.,&Wilcox, M. H. Antibodies for treatment of Clostridium difficile infection. Clin. Vaccine Immunol. 21, 913-923 (2014
84. Kelly, C. P., et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob. Agents Chemother. 41, 236-241 (1997
85. Warny, M., et al. Bovine immunoglobulin concentrate-Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44, 212-217 (1999
86. Numan, S. C., Veldkamp, P., Kuijper, E. J., van den Berg, R. J.,&van Dissel, J. T. Clostridium difficile-Associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 56, 888-889 (2007
87. Mattila, E., et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-Associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand. J. Infect. Dis. 40, 702-708 (2008
88. Sponseller, J. K., et al. Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J. Infect. Dis. 211, 1334-1341 (2015
89. Steele, J., Sponseller, J., Schmidt, D., Cohen, O.,&Tzipori, S. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum. Vaccin. Immunother. 9, 1565-1568 (2013
90. Panahi, Y., et al. Bovine colostrum in the management of nonorganic failure to thrive: a randomized clinical trial. J. Pediatr. Gastroenterol. Nutr. 50, 551-554 (2010
91. Salcedo, J., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41, 366-370 (1997
92. Abougergi, M. S.,&Kwon, J. H. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig. Dis. Sci. 56, 19-26 (2011
93. Lowy, I., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197-205 (2010
94. Steele, J., Mukherjee, J., Parry, N.,&Tzipori, S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J. Infect. Dis. 207, 323-330 (2013
95. Wilcox, M., et al. Phase 3 double-blind study of actoxumab (ACT)&bezlotoxumab (BEZ) for prevention of recurrent C. difficile infection (rCDI) in patients on standard of care (SoC) antibiotics (MODIFY I) [abstract]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2015 Sept 17-21; San Diego, CA (2015
96. Gerding, D., et al. Phase 3 double-blind study of bezlotoxumab (BEZ) alone&with actoxumab (ACT) for prevention of recurrent C. difficile infection (rCDI) in patients on standard of care (SoC) antibiotics (MODIFY II) [abstract]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, 2015 Sept 17-21; San Diego, CA (2015
97. Ghose, C.,&Kelly, C. P. The prospect for vaccines to prevent Clostridium difficile infection. Infect. Dis. Clin. North Am. 29, 145-162 (2015
98. Foglia, G., Shah, S., Luxemburger, C.,&Pietrobon, P. J. Clostridium difficile: development of a novel candidate vaccine. Vaccine 30, 4307-4309 (2012
99. Sougioultzis, S., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-Associated diarrhea. Gastroenterology 128, 764-770 (2005
100. Greenberg, R. N., Marbury, T. C., Foglia, G.,&Warny, M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30, 2245-2249 (2012
101. de Bruyn, G., et al. A Phase II study of the safety and immunogenicity of different formulations of a candidate Clostridium difficile toxoid vaccine: dose and formulation selection for Phase III (abstract E-2594). Presented at the 24th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2014 May 10-13; Barcelona, Spain (2015
102. de Bruyn, G., et al. A Phase II study of the safety and immunogenicity of different vaccination schedules of a candidate Clostridium difficile toxoid vaccine: vaccination schedule selection for Phase III (E-215). Presented at the 24th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2014 May 10-13; Barcelona, Spain (2015
103. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01887912?term=NCT01887912&rank=1 (2015
104. Donald, R. G., et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 159, 1254-1266 (2013
105. Tian, J. H., et al. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30, 4249-4258 (2012
106. Permpoonpattana, P., et al. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect. Immun. 79, 2295-2302 (2011
107. Pechine, S., et al. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 25, 3946-3954 (2007
108. Karczewski, J., et al. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine 32, 2812-2818 (2014
109. Kociolek, L. K., Patel, S. J., Shulman, S. T.,&Gerding, D. N. Concomitant medical conditions and therapies preclude accurate classification of children with severe or severe complicated Clostridium difficile infection. J. Pediatric Infect. Dis. Soc. 4, e139-e142 (2014